Will 3D model development reach its potential to innovate cell and gene therapeutics? We spoke to Merck, GlaxoSmithKline, East Carolina University Brody School of Medicine, and the Institute of Molecular Biotechnology to find out more.

Oxford Global's Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our April Discussion Group addressing ‘3D Model Development' brought together an exclusive panel of key opinion leaders to address the market's growth and future directions.

As market leaders in the biologics field, there is no sign of demand for antibody-based therapies slowing down any time soon. With exclusive insights from the CRUK-AstraZeneca Antibody Alliance Laboratory, we look towards the future of antibody discovery and optimisation.

Raymond R. Mattingly explains the applications of 3D cell culturing at Oxford Global's 3D Cell Culture Symposium.

Oxford Global’s Discussion Groups provide a focused networking opportunity for a handful of like-minded experts on a monthly basis. Our March Discussion Group addressing ‘Sustainable Synthesis of Therapeutic Oligonucleotides’ brought together an exclusive panel of key opinion leaders to address the market’s growth and future outlook.

While membrane proteins are inherently unstable and challenging to work with, Salipro Biotech are focusing on the stabilisation of challenging protein targets for a variety of downstream applications. This Commentary article explores how Salipro’s platform technology enables new opportunities for drug development.

Ian A Wilson of ImaginAb delivers the presentation ‘The Value of In Vivo Imaging on the Clinical Development of IO Drugs’ at Oxford Global’s discussion group.

Oxford Global’s Immuno Week showcased new ways of reprogramming the immune system to treat malignancy with TCR-T.

Early and effective treatment of cancers could mean the difference between life and death. Therefore, companion diagnostics and biomarker discovery could be considered one of the most important avenues to explore in immuno-oncology.

Experts discuss elusively successful therapies and the rising costs that come with new technologies.

RevoloBio’s autoimmunity drug, ‘1805, breaks with the mould in its revolutionary approach. With success in a Phase II clinical trial, scientists wonder what’s around the corner for the field.